Mul-1867 Inhalation Therapy for Pulmonary Exacerbations Caused by Burkholderia Cepacia in COPD and Cystic Fibrosis patients

Trial Profile

Mul-1867 Inhalation Therapy for Pulmonary Exacerbations Caused by Burkholderia Cepacia in COPD and Cystic Fibrosis patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs MUL 1867 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors TGV-Laboratories
  • Most Recent Events

    • 02 Mar 2016 According to a TGV Laboratories media release, the company has filed an application with the Food and Drug Administration seeking Orphan Drug Status for Mul-1867 to be tested on cystic fibrosis patients with life-threatening antimicrobial-resistant pulmonary infections.
    • 29 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top